Head and neck squamous cell cancer (stages III and IV) induction chemotherapy assessment: Value of FDG volumetric imaging parameters

Jielin Yu, Timothy Cooley, Minh Tam Truong, Gustavo Mercier, Rathan M. Subramaniam

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Introduction To evaluate whether the change in the metabolic tumour volume (MTV) or total lesion glycolysis (TLG) of the primary tumour, before and after induction chemotherapy, predicts outcome for patients with advanced head and neck squamous cell cancer (SCC). Methods Twenty-eight patients with advanced (American Joint Committee on Cancer stage III and IV) head and neck SCC who underwent positron emission tomography (PET)/CT were included in this retrospective study. Primary tumour MTV and TLG were measured using gradient and fixed percentage threshold segmentations. Outcome endpoint was disease progression or mortality. Pearson correlation, Bland-Altman and receiver operator characteristic analysis were performed. Results The Pearson's correlation coefficients between percentage changes (pre- and post-induction chemotherapy) from gradient MTV (MTVG) and the 38% SUVmax threshold MTV (MTV38) was 0.96 and between MTVG and the 50% threshold MTV (MTV50) was 0.95 (P < 0.0001). The corresponding Pearson r between TLGG and TLG38 was 0.94 and between TLGG and TLG50 was 0.96 (P < 0.0001). The least bias was 1.89% (standard deviation = 25.30%) between the percentage changes of MTVG and MTV50. The areas under the curve for predicting progression or mortality were 0.76 (P = 0.03) for MTVG and 0.82 for TLGG (P = 0.009). Optimum cut points of a 42% reduction in MTV G and a 55% reduction in the TLGG predict event-free survival with a sensitivity of 62.5% and a specificity of 90% and a hazards ratio of 6.25. Conclusion A reduction in primary tumour MTV of at least 42% or in TLG of at least 55% after induction chemotherapy may predict event-free survival in patients with advanced head and neck SCC.

Original languageEnglish (US)
Pages (from-to)18-24
Number of pages7
JournalJournal of Medical Imaging and Radiation Oncology
Volume58
Issue number1
DOIs
StatePublished - Feb 1 2014

Fingerprint

Squamous Cell Neoplasms
Induction Chemotherapy
Head and Neck Neoplasms
Tumor Burden
Head
Glycolysis
Disease-Free Survival
Neoplasms
Mortality
Positron-Emission Tomography
Area Under Curve
Disease Progression
Retrospective Studies

Keywords

  • head and neck
  • PET/CT

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Oncology
  • Medicine(all)

Cite this

Head and neck squamous cell cancer (stages III and IV) induction chemotherapy assessment : Value of FDG volumetric imaging parameters. / Yu, Jielin; Cooley, Timothy; Truong, Minh Tam; Mercier, Gustavo; Subramaniam, Rathan M.

In: Journal of Medical Imaging and Radiation Oncology, Vol. 58, No. 1, 01.02.2014, p. 18-24.

Research output: Contribution to journalArticle

@article{52abb960f93d49eeb6b9bfca01979c7b,
title = "Head and neck squamous cell cancer (stages III and IV) induction chemotherapy assessment: Value of FDG volumetric imaging parameters",
abstract = "Introduction To evaluate whether the change in the metabolic tumour volume (MTV) or total lesion glycolysis (TLG) of the primary tumour, before and after induction chemotherapy, predicts outcome for patients with advanced head and neck squamous cell cancer (SCC). Methods Twenty-eight patients with advanced (American Joint Committee on Cancer stage III and IV) head and neck SCC who underwent positron emission tomography (PET)/CT were included in this retrospective study. Primary tumour MTV and TLG were measured using gradient and fixed percentage threshold segmentations. Outcome endpoint was disease progression or mortality. Pearson correlation, Bland-Altman and receiver operator characteristic analysis were performed. Results The Pearson's correlation coefficients between percentage changes (pre- and post-induction chemotherapy) from gradient MTV (MTVG) and the 38{\%} SUVmax threshold MTV (MTV38) was 0.96 and between MTVG and the 50{\%} threshold MTV (MTV50) was 0.95 (P < 0.0001). The corresponding Pearson r between TLGG and TLG38 was 0.94 and between TLGG and TLG50 was 0.96 (P < 0.0001). The least bias was 1.89{\%} (standard deviation = 25.30{\%}) between the percentage changes of MTVG and MTV50. The areas under the curve for predicting progression or mortality were 0.76 (P = 0.03) for MTVG and 0.82 for TLGG (P = 0.009). Optimum cut points of a 42{\%} reduction in MTV G and a 55{\%} reduction in the TLGG predict event-free survival with a sensitivity of 62.5{\%} and a specificity of 90{\%} and a hazards ratio of 6.25. Conclusion A reduction in primary tumour MTV of at least 42{\%} or in TLG of at least 55{\%} after induction chemotherapy may predict event-free survival in patients with advanced head and neck SCC.",
keywords = "head and neck, PET/CT",
author = "Jielin Yu and Timothy Cooley and Truong, {Minh Tam} and Gustavo Mercier and Subramaniam, {Rathan M.}",
year = "2014",
month = "2",
day = "1",
doi = "10.1111/1754-9485.12081",
language = "English (US)",
volume = "58",
pages = "18--24",
journal = "Journal of Medical Imaging and Radiation Oncology",
issn = "1754-9477",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Head and neck squamous cell cancer (stages III and IV) induction chemotherapy assessment

T2 - Value of FDG volumetric imaging parameters

AU - Yu, Jielin

AU - Cooley, Timothy

AU - Truong, Minh Tam

AU - Mercier, Gustavo

AU - Subramaniam, Rathan M.

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Introduction To evaluate whether the change in the metabolic tumour volume (MTV) or total lesion glycolysis (TLG) of the primary tumour, before and after induction chemotherapy, predicts outcome for patients with advanced head and neck squamous cell cancer (SCC). Methods Twenty-eight patients with advanced (American Joint Committee on Cancer stage III and IV) head and neck SCC who underwent positron emission tomography (PET)/CT were included in this retrospective study. Primary tumour MTV and TLG were measured using gradient and fixed percentage threshold segmentations. Outcome endpoint was disease progression or mortality. Pearson correlation, Bland-Altman and receiver operator characteristic analysis were performed. Results The Pearson's correlation coefficients between percentage changes (pre- and post-induction chemotherapy) from gradient MTV (MTVG) and the 38% SUVmax threshold MTV (MTV38) was 0.96 and between MTVG and the 50% threshold MTV (MTV50) was 0.95 (P < 0.0001). The corresponding Pearson r between TLGG and TLG38 was 0.94 and between TLGG and TLG50 was 0.96 (P < 0.0001). The least bias was 1.89% (standard deviation = 25.30%) between the percentage changes of MTVG and MTV50. The areas under the curve for predicting progression or mortality were 0.76 (P = 0.03) for MTVG and 0.82 for TLGG (P = 0.009). Optimum cut points of a 42% reduction in MTV G and a 55% reduction in the TLGG predict event-free survival with a sensitivity of 62.5% and a specificity of 90% and a hazards ratio of 6.25. Conclusion A reduction in primary tumour MTV of at least 42% or in TLG of at least 55% after induction chemotherapy may predict event-free survival in patients with advanced head and neck SCC.

AB - Introduction To evaluate whether the change in the metabolic tumour volume (MTV) or total lesion glycolysis (TLG) of the primary tumour, before and after induction chemotherapy, predicts outcome for patients with advanced head and neck squamous cell cancer (SCC). Methods Twenty-eight patients with advanced (American Joint Committee on Cancer stage III and IV) head and neck SCC who underwent positron emission tomography (PET)/CT were included in this retrospective study. Primary tumour MTV and TLG were measured using gradient and fixed percentage threshold segmentations. Outcome endpoint was disease progression or mortality. Pearson correlation, Bland-Altman and receiver operator characteristic analysis were performed. Results The Pearson's correlation coefficients between percentage changes (pre- and post-induction chemotherapy) from gradient MTV (MTVG) and the 38% SUVmax threshold MTV (MTV38) was 0.96 and between MTVG and the 50% threshold MTV (MTV50) was 0.95 (P < 0.0001). The corresponding Pearson r between TLGG and TLG38 was 0.94 and between TLGG and TLG50 was 0.96 (P < 0.0001). The least bias was 1.89% (standard deviation = 25.30%) between the percentage changes of MTVG and MTV50. The areas under the curve for predicting progression or mortality were 0.76 (P = 0.03) for MTVG and 0.82 for TLGG (P = 0.009). Optimum cut points of a 42% reduction in MTV G and a 55% reduction in the TLGG predict event-free survival with a sensitivity of 62.5% and a specificity of 90% and a hazards ratio of 6.25. Conclusion A reduction in primary tumour MTV of at least 42% or in TLG of at least 55% after induction chemotherapy may predict event-free survival in patients with advanced head and neck SCC.

KW - head and neck

KW - PET/CT

UR - http://www.scopus.com/inward/record.url?scp=84894259629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894259629&partnerID=8YFLogxK

U2 - 10.1111/1754-9485.12081

DO - 10.1111/1754-9485.12081

M3 - Article

C2 - 24529051

AN - SCOPUS:84894259629

VL - 58

SP - 18

EP - 24

JO - Journal of Medical Imaging and Radiation Oncology

JF - Journal of Medical Imaging and Radiation Oncology

SN - 1754-9477

IS - 1

ER -